Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
PaperCitations, authors & open-access status
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 218 citations, 2018 year and green oa status.
218
Citations
2018
Year
green
OA Status